Werewolf Therapeutics (NASDAQ:HOWL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) to a sell rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics presently has an average rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $0.37 on Friday. The stock has a fifty day moving average of $0.38 and a two-hundred day moving average of $0.60. The company has a market capitalization of $17.87 million, a PE ratio of -0.48 and a beta of 0.29. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.36. The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $21.00 million. As a group, equities research analysts forecast that Werewolf Therapeutics will post -1.08 earnings per share for the current fiscal year.

Insider Activity at Werewolf Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the completion of the transaction, the insider owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Luke Evnin sold 305,741 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70. Following the transaction, the director directly owned 1,273,008 shares in the company, valued at approximately $891,105.60. This represents a 19.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,579,847 shares of company stock valued at $1,712,621 in the last ninety days. 23.60% of the stock is currently owned by company insiders.

Institutional Trading of Werewolf Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in HOWL. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the second quarter valued at $48,000. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.